Nektar, Bristol Myers Squibb end clinical development of combination therapy including OpdivoMarket Watch • 04/18/22
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)PRNewsWire • 04/14/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTRPRNewsWire • 03/26/22
Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical BenefitBenzinga • 03/14/22
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 TrialPRNewsWire • 03/14/22
Nektar's stock falls 44% after experimental therapy fails to work in melanoma patientsMarket Watch • 03/14/22
Nektar Therapeutics' (NKTR) CEO Howard Robin on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/01/22
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial MarketsPRNewsWire • 02/17/22
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare ConferencePRNewsWire • 01/05/22
Is the Options Market Predicting a Spike in Nektar Therapeutics (NKTR) Stock?Zacks Investment Research • 12/31/21
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic DermatitisPRNewsWire • 12/15/21
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual MeetingPRNewsWire • 12/13/21